Their press release gave just enough information to get them off the hook for any future class action suits, but still fools the naive investors until they unload their million shares.
In a trial like this, the safety endpoint and efficacy endpoint are usually the same - death, or time to death. When they anounced that the GDT stent is safe (did they say anecdotal?), or not many more deaths than placebo, they basically admitted it had no effect. Unless miracle happens, such as an accelarated deaths happen in the placebo treatment group in the next 3 months (Oh no! May God bless every patient!), GDT is a dead man walking!